Welcome to our dedicated page for Ocuphire Pharma SEC filings (Ticker: OCUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocuphire Pharma’s SEC disclosures run hundreds of pages, packed with clinical-trial data, R&D accounting and complex licensing terms—details that can blur together when you just want to know whether APX3330 hit its study goals or how much cash runway remains. Our platform solves that problem by turning every Ocuphire Pharma SEC filing into plain-English insights the moment it hits EDGAR.
Need the numbers fast? The Ocuphire Pharma quarterly earnings report 10-Q filing is parsed for trial spend, partnership revenue and burn rate within seconds. Wondering if executives bought shares before new data? Check Ocuphire Pharma insider trading Form 4 transactions—we stream them in real time and flag patterns such as option exercises. Material trial updates? Our summaries of the latest Ocuphire Pharma 8-K material events explained show why the news matters without medical jargon.
Here’s what you can explore today:
- Ocuphire Pharma annual report 10-K simplified—AI highlights pipeline timelines, Ref-1 science and risk factors.
- Ocuphire Pharma Form 4 insider transactions real-time—track executive stock moves and set custom alerts.
- Ocuphire Pharma proxy statement executive compensation—compare stock-option grants to clinical milestones.
- Ocuphire Pharma earnings report filing analysis—view cash usage trends quarter over quarter.
From understanding Ocuphire Pharma SEC documents with AI to monitoring Ocuphire Pharma executive stock transactions Form 4, Stock Titan delivers every disclosure, summarized, searchable and always current. Spend minutes, not hours, getting the story behind OCUP’s drug-development journey.
Robert E. Gagnon, Chief Financial Officer and Director of Opus Genetics, Inc., reported two equity grants to himself. The filing shows a grant of 200,000 restricted stock units on September 10, 2025 that vest 25% on September 2, 2026 with the remainder vesting monthly over the next 36 months, subject to continued service. It also shows an employee stock option granted on September 2, 2025 to purchase 250,000 shares at an exercise price of $1.23; the option will vest 25% on September 2, 2026 with the remainder vesting monthly over 36 months and shows an expiration/related date of September 1, 2035. Following these grants, the reporter beneficially owned 200,000 common shares from the RSUs and 250,000 underlying shares from the option, each reported as direct ownership. The form is signed by a power of attorney on behalf of the reporting person on September 11, 2025.
Robert E. Gagnon, listed at C/O Opus Genetics, Inc., filed an Initial Form 3 reporting his relationship to the issuer as a director and Chief Financial Officer. The event date is 09/02/2025. The filing states no securities are beneficially owned and includes Exhibit 24 (Power of Attorney). The form was signed by Amy Rabourn by power of attorney on 09/11/2025.
Opus Genetics, Inc. filed a Registration Statement on Form S-8 dated September 10, 2025 to register securities under an employee benefit plan. The filing incorporates by reference the companys 2024 Annual Report (filed March 31, 2025), quarterly reports filed May 15 and August 13, 2025, numerous Form 8-Ks through September 2, 2025, and the Form 8-A description of common stock. The filing lists exhibits and includes a power of attorney and officer and director signatures authorizing the submission.
Opus Genetics, Inc. director Gallagher Cam reported a purchase of 869,565 shares of the issuer's common stock on 08/25/2025 at a price of $1.15 per share. After the transaction the reporting person beneficially owned 1,810,430 shares. The Form 4 was submitted by power of attorney on 08/27/2025.
Opus Genetics, Inc. director Sean Ainsworth reported an open-market purchase of 86,956 shares of the company's common stock on 08/25/2025 at a price of $1.15 per share, increasing his beneficial ownership to 254,818 shares. The Form 4 was signed via power of attorney on 08/27/2025. The filing shows no reported derivative transactions.
Opus Genetics, Inc. disclosed that Nantahala Capital Management, LLC and two individuals associated with it each may be deemed the beneficial owner of 6,250,299 shares of the company’s common stock, representing 9.99% of the class. The reported total includes 2,904,378 shares that may be acquired within 60 days upon exercise of warrants, and all reported shares are held with shared voting and dispositive power (no sole voting or dispositive power). The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control. A fund advised by Nantahala, Blackwell Partners LLC - Series A, has the right to receive dividends or sale proceeds for more than 5% of the reported shares.
Opus Genetics, Inc. reported license and collaboration revenue of $2.882 million for the quarter and $7.252 million for the six months, up from $1.112 million and $2.823 million a year earlier. Operating expenses rose to $11.8 million in the quarter (research and development $6.0 million; general and administrative $5.8 million), producing a net loss of $7.42 million for the quarter and $15.614 million for the six-month period, with basic and diluted loss per share of $(0.12) and $(0.32), respectively.
The balance sheet shows $32.4 million in cash and cash equivalents and total assets of $38.7 million. Total liabilities were $21.2 million, including $11.8 million of warrant liabilities recorded in connection with March 2025 financings that produced combined gross proceeds of approximately $21.5 million. The Company had 59,908,055 shares outstanding as of the reported count and states its current cash is sufficient to fund planned expenditures for at least twelve months. The filing discloses sizeable potential milestone obligations under acquired licenses (including maximums of $111.7 million, $76.4 million and $93.5 million for certain agreements) that were not recorded because they were not deemed probable.
Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.
FAQ
What is the current stock price of Ocuphire Pharma (OCUP)?
What is the market cap of Ocuphire Pharma (OCUP)?
